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orty million Americans are afflicted with chronic
disorders of sleep and wakefulness,which interfere with
work,driving,and social activities.Sleep disorders cause
38 000 cardiovascular deaths and cost over $16 billion
annually.
1 Indirect costs of accidents,property destruc-
tion,litigation,hospitalization,and death add another $50
to $100 billion.
1 The most common sleep disorders
include insomnia, sleep apnea, restless legs syndrome,
and narcolepsy.
1-3
Classification of sleep disorders
The International Classification of Sleep Disorders diag-
nostic and coding manual 2000 lists four major categories
of sleep disorders:dyssomnias;parasomnias;sleep disor-
ders associated with mental,neurologic,or other medical
disorders;and proposed sleep disorders (Table I).
4-7
Dyssomnias are disorders characterized by either exces-
sive sleepiness or difficulty initiating or maintaining sleep.
4
On the basis of pathophysiological mechanisms,they can
be subdivided into intrinsic, extrinsic, and circadian
rhythm sleep disorders.
4-9 Intrinsic sleep disorders are dis-
orders that originate or develop within the body or that
arise from causes within the body.Common intrinsic sleep
disorders include idiopathic and psychophysiological
insomnia,narcolepsy,obstructive sleep apnea syndrome
(OSAS),periodic limb movement disorder (PLMD),and
restless legs syndrome (RLS).
4-7 Sleep disorders caused by
external factors are termed extrinsic sleep disorders and
include inadequate sleep hygiene, environmental sleep
disorder,adjustment sleep disorder,insufficient sleep syn-
drome,limit-setting sleep disorder,sleep-onset association
Clinical research
Keywords: diagnosis; treatment; sleep disorder; insomnia; circadian rhythm
disorder; excessive somnolence; parasomnia
Author affiliations: Stanford University Sleep Disorders Clinic and Research
Center, Stanford University, School of Medicine, Stanford, Calif, USA
Address for correspondence: Christian Guilleminault, MD, Professor of
Psychiatry and Behavioral Sciences and Director of Training, Stanford Sleep
Disorders Center, 401 Quarry Road, Suite 3301, Stanford, CA 94305, USA
(e-mail: cguil@stanford.edu)
F
Copyright © 2003 LLS SAS.  All rights reserved www.dialogues-cns.org
Diagnosis and treatment of sleep disorders:
a brief review for clinicians
Vivien C.Abad, MD, MBA; Christian Guilleminault, MD
Sleep disorders encompass a wide spectrum of diseases
with significant individual health consequences and high
economic costs to society. To facilitate the diagnosis and
treatment of sleep disorders, this review provides a
framework using the International Classification of Sleep
Disorders. Primary and secondary insomnia are differen-
tiated, and pharmacological and nonpharmacological
treatments are discussed. Common circadian rhythm dis-
orders are described in conjunction with interventions,
including chronotherapy and light therapy. The diagno-
sis and treatment of restless legs syndrome/periodic limb
movement disorder is addressed. Attention is focused on
obstructive sleep apnea and upper airway resistance syn-
drome, and their treatment. The constellation of symp-
toms and findings in narcolepsy are reviewed together
with diagnostic testing and therapy. Parasomnias, includ-
ing sleep terrors, somnambulism, and rapid eye move-
ment (REM) behavior sleep disorders are described,
together with associated laboratory testing results and
treatment.
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sleep disorder.
4-7 Circadian rhythm sleep disorders share
a common chronophysiological basis whereby there is a
discordance between the patient’s sleep pattern and the
desired or societal sleep norm.
4-9 Examples of circadian
rhythm sleep disorders include shift work sleep disorder,
delayed sleep phase syndrome,and advanced sleep phase
syndrome.
Parasomnias are characterized by undesirable behavioral
and physical phenomena that occur predominantly dur-
ing sleep.
4-7 They include disorders of arousal, partial
arousal,and sleep-stage transition.
Sleep disorders can also be associated with mental dis-
orders,such as psychoses,mood disorders,anxiety disor-
ders,panic disorders,and alcoholism.Neurological con-
ditions associated with sleep disorders include cerebral
degenerative disorders, dementia, parkinsonism, fatal
familial insomnia,sleep-related epilepsy,electrical status
epilepticus of sleep,and sleep-related headaches.
4,10 Sleep
disorders can occur with medical disorders,such as sleep-
ing sickness,nocturnal cardiac ischemia,chronic obstruc-
tive pulmonary disease, sleep-related asthma, sleep-
related gastroesophageal reflux, peptic ulcer disease,
irritable bowel syndrome and fibromyalgia.
4,11-14
Proposed sleep disorders include short sleeper, long
sleeper, subwakefulness syndrome, fragmentary myo-
clonus,sleep hyperhidrosis,menstrual-associated sleep
disorder,pregnancy-associated sleep disorder,terrifying
hypnagogic hallucinations, sleep-related neurogenic
tachypnea,sleep-related laryngospasm,and sleep chok-
ing syndrome.
4
Approach to sleep disorders
History and physical examination
An accurate and detailed history from the patient,bed
partner,or family member combined with a sleep ques-
tionnaire can elicit critical information.Most sleep com-
plaints fall into three categories:insomnia (sleep onset,
maintenance, or early morning awakening); excessive
sleepiness;or abnormal behaviors during sleep.The pro-
cedure is as follows.
• Inquire into the chief complaint, when symptom(s)
started,the pattern since onset,and associated factors
(medical, environmental, occupational, psychologi-
cal/stress,lifestyle choices) that may have predisposed
to or precipitated the illness, perpetuated the condi-
tion,and improved or worsened symptoms.
7
•Assess the impact of the sleep complaint on the
patient’s life,and inquire about meal and sleep sched-
ules,sleep hygiene,restless legs sensation,snoring,wit-
nessed apneic episodes, sweating, coughing, gasping/
choking/snorting, dryness of the mouth, bruxism,
excessive movements during sleep, periodic limb
movements,any abnormal behaviors during sleep,day-
time sleepiness,presence of cataplexy,sleep paralysis,
and hypnagogic or hypnapompic hallucinations.
•Ask about caffeine intake,alcohol and nicotine use,as
well as use of illicit drugs.
• Review the pertinent medical/surgical/psychiatric his-
tory and past treatments, and their efficacy or lack
thereof.
• Determine if there is any family history of sleep disor-
ders (snoring,OSAS,narcolepsy,RLS).
A completed 2-week sleep log or sleep diary can be uti-
lized to compute sleep efficiency, total sleep time, and
number of awakenings during the night,and can be used
to diagnose sleep disorders and monitor efficacy of treat-
ment. On the basis of the information from question-
naires and sleep diary,the chief complaint,and the his-
tory,a working diagnosis is outlined.
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Selected abbreviations and acronyms
AHI  apnea-hypopnea index
BIPAP bilevel positive airway pressure
CPAP continuous positive airway pressure
EDS excessive daytime somnolence
EMG electromyogram
EOG electro-oculogram
MSLT mean sleep latency test
MWT maintenance of wakefulness test
NPT nocturnal penile tumescence
NREM non–rapid eye movement
OSAS obstructive sleep apnea syndrome
PLMD periodic limb movement disorder
PMR progressive muscle relaxation
PSG polysomnogram
RBD REM behavior sleep disorder
RDI respiratory disturbance index
REM rapid eye movement
RLS restless legs syndrome
SOL sleep-onset latency
SWS slow-wave sleep
UARS upper airway resistance syndrome
WASO wake after sleep onsetDiagnosis and treatment of sleep disorders - Abad and Guilleminault Dialogues in Clinical Neuroscience - Vol 5 . No.4 . 2003
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Dyssomnias Parasomnias Sleep disorders associated with  Proposed sleep disorders
mental,neurological, or other 
medical disorders
• Intrinsic sleep disorders
- Psychophysiological insomnia
- Sleep state misperception
- Idiopathic insomnia
- Narcolepsy
- Recurrent hypersomnia
- Idiopathic hypersomnia
- Posttraumatic hypersomnia
- Central alveolar hypo-
ventilation syndrome
- Periodic limb movement 
disorder
- Restless legs syndrome
- Intrinsic sleep disorder NOS
• Extrinsic sleep disorders
- Inadequate sleep hygiene 
- Environmental sleep disorder
- Altitude insomnia
- Adjustment sleep disorder
- Insufficient sleep syndrome
- Limit-setting sleep disorder
- Sleep-onset association 
disorder
- Food allergy insomnia
- Nocturnal eating (drinking)
syndrome
- Hypnotic-dependent sleep
disorder
- Stimulant-dependent sleep
disorder
- Toxin-induced sleep disorder
- Extrinsic sleep disorder NOS
• Circadian rhythm sleep 
disorders
- Jet lag syndrome
- Shift work sleep disorder
- Irregular sleep-wake pattern
- Delayed sleep-phase 
syndrome
- Advanced sleep-phase 
syndrome
- Non–24-h sleep-wake 
disorder
- Circadian rhythm sleep 
disorder NOS
• Arousal disorders
- Confusional arousals
- Sleepwalking
- Sleep terrors
• Sleep-wake transition 
disorders
- Rhythmic starts
- Sleep starts
- Sleep talking
- Nocturnal leg cramps
• Parasomnias usually 
associated with REM sleep
- Nightmares
- Sleep paralysis
- Impaired sleep-related penile
erections
- REM sleep-related sinus
arrest
- REM sleep behavior disorder
• Other parasomnias
- Sleep bruxism
- Sleep enuresis
- Sleep-related abnormal 
swallowing syndrome
- Nocturnal paroxysmal 
dystonia
- Sudden unexplained 
nocturnal death syndrome
- Primary snoring
- Infant sleep apnea
- Congenital central hypo-
ventilation syndrome
- Sudden infant death 
syndrome
- Benign neonatal sleep
myoclonus
- Other parasomnias NOS
• Associated with mental dis-
orders
- Psychoses
- Mood disorders
- Anxiety disorders
- Panic disorders
- Alcoholism
• Associated with neurological
disorders
- Cerebral degenerative 
disorders
- Dementia
- Parkinsonism
- Fatal familial insomnia
- Sleep-related epilepsy
- Electrical status epilepticus of
sleep
- Sleep-related headaches
• Associated with other 
medical disorders
- Chronic obstructive 
pulmonary disease
- Sleep-related asthma
- Sleep-related gastroesopha-
geal reflux
- Peptic ulcer disease
- Fibromyalgia
- Short sleeper
- Long sleeper
- Subwakefulness syndrome
- Fragmentary myoclonus
- Sleep hyperhidrosis
- Menstrual-associated sleep
disorder
- Pregnancy-associated sleep
disorder
- Terrifying hypnagogic 
hallucinations
- Sleep-related neurogenic
tachypnea
- Sleep-related laryngospasm
- Sleep-choking syndrome
Table I. Classification of sleep disorders.
4 NOS, not otherwise specified; REM, rapid eye movement.Laboratory studies
Laboratory tests that are performed to assess and there-
fore treat sleep disorders include the polysomnogram
(PSG),multiple sleep latency test (MSLT),maintenance of
wakefulness test (MWT),actigraphy,video-PSG,noctur-
nal penile tumescence monitoring (NPT),and electroen-
cephalography (EEG),including 24-h ambulatory EEG.
PSG is a complete,nocturnal,laboratory-based monitor-
ing,which simultaneously records numerous variables dur-
ing sleep.It includes sleep staging (EEG),electro-oculo-
gram (EOG),submental electromyogram (EMG),nasal
or oral airflow,respiratory effort,oximetry,electrocardio-
gram (ECG),anterior tibialis EMG,and position moni-
toring.Depending upon the clinical diagnosis,additional
parameters may be added:transcutaneous CO2 monitor-
ing or end-tidal gas analysis; extremity muscle activity;
motor activity movement; extended video-EEG; penile
tumescence;esophageal pressure;gastroesophageal reflux;
snoring;and continuous blood pressure recording.
15-17
Modified forms of PSG include daytime nap PSG,split-
night studies,and portable recording studies.
18-21 Daytime
PSG is reported to have a high negative predictive value
(95% when the apnea-hypopnea index [AHI] ≥10) for
OSAS,but results are inconsistent.
18 Split-night studies
may save time and money, but it is still controversial
whether diagnosis and treatment are adequately estab-
lished.
21,22 The American Academy of Sleep Medicine
(AASM) has formulated guidelines for the use of PSGs,
split-night studies,and portable recordings.
15,16,19
The MSLT is used to confirm the diagnosis of narcolepsy;
to assess complaints of moderate to severe sleepiness in
patients with mild to moderate OSAS,idiopathic hyper-
somnia, PLMD, some circadian rhythm disorders, and
unknown causes of excessive sleepiness;to evaluate the
complaint of insomnia when moderate to severe exces-
sive daytime sleepiness is suspected; and to assess
response to treatment following therapy for disorders that
cause sleepiness when an additional sleep disorder that
produces sleepiness is suspected.
23,24The MWT is used less
commonly than the MSLT mainly to assess improved
alertness following therapeutic interventions.
23-25
Actigraphy uses a small portable device that senses phys-
ical motion and stores the resulting information.
Actigraphic studies need to be conducted for a minimum
of three consecutive 24-h periods.
26,27The AASM Standards
of Practice Committee recently updated practice parame-
ters which state that actigraphy is not indicated for the rou-
tine diagnosis,assessment of severity,or management of
any of the sleep disorders.
28 However,it may be a useful
adjunct that provides objective demonstration of multiday
rest/activity patterns, which can be used to assist in the
diagnosis, treatment, and/or assessment of treatment
effects in various sleep disorders,including insomnia,cir-
cadian rhythm disorders, RLS/PLMD, and disorders of
excessive sleepiness.
26
Video-PSG may be helpful in the diagnosis of patients
with arousal disorders or other sleep disruptions that are
believed to be seizure-related.
15,16 NPT for sleep-related
erections (SRE) is an adjunct in the diagnosis of impo-
tence.
29 It usually requires 2 nights of PSG, although 1
night is sufficient if SRE is normal.Twenty-four hours of
EEG is monitored for patients with suspected epilepsy.
Description of common sleep disorders
It is beyond the scope of this review to describe the entire
gamut of sleep disorders.We will focus on the following
common or severe sleep disorders: insomnia, circadian
rhythm disorders,disorders of excessive somnolence (sleep
apnea,narcolepsy,RLS/PLMD),and parasomnias.
Insomnia
Insomnia refers to almost nightly complaints of insuffi-
cient amounts of sleep or not feeling rested after the
habitual sleep episode. As the most common sleep-
wake–related disorder,it is more common in women and
has a prevalence ranging from 10% to 30%.
2,3 It can be
classified based on severity (mild,moderate,severe) or
duration (acute,subacute,chronic).
4Transient insomnia
can occur in adjustment sleep disorders triggered by
acute stress,travel,or sleeping in an unfamiliar environ-
ment.
7 Symptoms usually resolve once the stress is
reduced or removed,or the individual’s adaptation to the
stressor increases.For transient insomnia,treatment con-
sists of education and advice about healthy sleep prac-
tices.If these are insufficient,short-term treatment with
hypnotics can be undertaken.
Chronic insomnia may be primary,or secondary to cir-
cadian rhythm,environmental,behavioral,medical,neu-
rological,and psychiatric disorders.Vgontzas et al and
Rodenback and Hajak reported nyctohemeral activation
of the hypothalamic-pituitary-adrenal axis (HPA) in
patients with chronic insomnia consistent with the
arousal theory of insomnia.
30,31 Vgontzas et al demon-
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factor (TNF) secretion from nighttime to daytime in
chronic insomniacs, and postulated that these could
explain the daytime fatigue and performance decrements
associated with insomnia.
32,33
The diagnosis of primary insomnia requires exclusion of
the direct physiological effects of a substance or general
medical condition.It does not occur exclusively during the
course of a mental disorder or other sleep disorder.
Among the primary insomnias,idiopathic insomnia rep-
resents a lifelong sleep disturbance associated with reduc-
tion in daytime alertness and performance,increased sleep
latency,and decreased sleep efficiency on PSG.
4 Other pri-
mary insomnias include psychophysiological insomnia and
sleep-state misperception.Psychophysiological insomnia
refers to maladaptive sleep-preventing behaviors,which
perpetuate the sleep disturbance.Typically,these patients
sleep better in any place other than their own bedroom.
PSG shows increased sleep latency,increased number of
awakenings,and poor sleep efficiency.Sleep-state misper-
ception refers to complaints of sleep difficulties with no
PSG evidence of significant sleep disturbance;the sleep
latency,quality,and architecture are normal.Inadequate
sleep hygiene and behavioral disorders can also produce
chronic insomnia.
4 Limit-setting disorder occurs in 5% to
10% of children and is characterized by refusal to go to
sleep when asked to do so and delaying bedtime;the PSG
is normal.
4,7
Secondary insomnia can result from medical,neurolog-
ical,environmental,drugs,or psychiatric causes.Medical
causes include pain,thyroid disease,acid reflux,coronary
artery disease,pulmonary disease (chronic obstructive
pulmonary disease,asthma,sleep apnea,central alveolar
hypoventilation syndrome),chronic renal insufficiency,
eating disorders, thyroid dysfunction, fibromyalgia,
menstrual-associated sleep disorder,and pregnancy.
34-36
Neurological causes of insomnia include headaches,
Parkinson’s disease,and sleep-related movement disor-
ders (nocturnal myoclonus,RLS).Environmental sleep
disorders can be triggered by excessive noise, noxious
odors,bright light,or extremes of ambient temperature.
Alcohol-,hypnotic-,and stimulant-dependent sleep dis-
orders also contribute to chronic insomnia.
Psychiatric disorders are characterized by sleep-onset dif-
ficulties,frequent arousals,sleep fragmentation,shortened
total sleep time,and decreased sleep efficiency.These dis-
orders include alcoholism,anxiety disorders,mood disor-
ders,panic disorders,and psychoses.Preliminary data indi-
cate that chronic insomnia may precede depressive
episodes by several years,and the question of systematic
treatment of chronic insomnia as a means of avoiding
depression is being studied.Stressful life events can pre-
cipitate chronic insomnia in predisposed individuals with
neurotic depression,rumination,chronic anxiety,inhibi-
tion of emotions,and inability to express anger.
36 PSG in
anxiety disorders shows increased sleep latency,decreased
rapid eye movement (REM) sleep,and reduced sleep effi-
ciency,while PSG in mood disorders demonstrates fre-
quent arousals and awakenings, decreased slow-wave
sleep (SWS), decreased REM latency, increased first
REM period duration, and increased REM density.
34
Insomnia assessment tools can utilize self-reporting meth-
ods (sleep diary and Pittsburgh Sleep Quality Index) and
objective methods include actigraphy and PSG.
26,37
Treatment for insomnia can be categorized into pharma-
cological and nonpharmacological treatments.Pharma-
cological strategies must achieve a balance between hyp-
notic and adverse effects. Hypnotics are indicated in
psychophysiological insomnia for occasional intermittent
use or short-term (2 weeks) administration. Benzo-
diazepine usage can result in impaired sleep quality,resid-
ual sedation,memory or functional impairment the day
following drug administration, or rebound insomnia.
Other problems may include increased rates of falls,
drowsiness,dizziness,cognitive impairment,and automo-
bile accidents.
35,38-40 Nonbenzodiazepine hypnotics,type I
selective γ-aminobutyric acid (GABA) receptor agents,
such as zolpidem (t1/2=2.4 h),zopiclone (t1/2=5 h),and zale-
plon (t1/2=1 h),have hypnosedative action similar to the
benzodiazepines and interact preferentially with ω1 recep-
tors.
41 Nonbenzodiazepines preserve psychomotor tasks
and memory capacities better than benzodiazepines and
do not possess respiratory depressive side effects.
35 Petit
and colleagues suggest that pharmacological therapy be
limited to 4 weeks.
35
Nonpharmacological treatments for chronic insomnia
include stimulus control therapy,sleep restriction,sleep
hygiene education,cognitive therapy,paradoxical inten-
tion, relaxation therapy and multicomponent ther-
apy.
34,35,42-48 Stimulus control therapy is based on the
premise that insomnia is a conditioned response to tem-
poral (bedtime) and environmental (bed/bedroom cues)
that are typically associated with sleep.
34 Interventions
result in reduction of sleep-onset latency (SOL) and
wake after sleep onset (WASO) to 30 min or less,with
total sleep time increased by 30 to 40 min.
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decreases sleep latency, and promotes more efficient
sleep,with less internight variability.
34 Interventions cur-
tail the amount of time spent in bed to match sleep effi-
ciency as determined through sleep diaries or actigraphy,
with a caveat of a minimum of 5 h in bed.Adjustments
are made weekly until optimal sleep duration is achieved.
Sleep hygiene education promotes better sleep through
awareness of environmental factors (light,noise,temper-
ature,and mattress) and health practices (diet,exercise,
and substance use) that may be beneficial or detrimental
to sleep.Poor sleep hygiene complicates insomnia and hin-
ders progress in therapy.Guilleminault et al reported sta-
tistically significant improvement at the end of 4 weeks in
insomnia patients treated with sleep hygiene and light
treatment.
48
Cognitive therapy identifies patient-specific dysfunctional
sleep cognition,challenges their validity,and replaces them
with more adaptive substitutes using attention shifting,
decatastrophizing,reappraisal,reattribution testing,and
hypotheses testing.
34,37,42,44,46
Paradoxical intention is a form of cognitive restructuring
to alleviate performance anxiety and is based on the
premise that performance anxiety hinders sleep onset.
34
It is a method that consists of persuading a patient to
engage in his most feared behavior,ie,staying awake.
Relaxation treatments include progressive muscle relax-
ation (PMR),imagery training,meditation,and biofeed-
back. Meta-analyses of PMR trials have demonstrated
reduced SOL and WASO by an average of 20 to 30 min
from baseline to posttreatment with equivalent increases
in total sleep time in addition to enhanced perception of
sleep quality.
34,35 Studies on imagery training have
yielded variable results.
34,35 Three studies on meditation
demonstrated significant improvements in SOL or
WASO.
34 Biofeedback training reduced SOL with
improvement rates similar to those obtained with stan-
dard relaxation procedures.
35Various nonpharmacolog-
ical treatments may be combined as multicomponent
therapy. Table II lists a combination of interventions
derived from stimulus control therapy, sleep restriction
therapy,sleep hygiene,and light therapy.
Clinical research
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Table II. Multicomponent therapy instructions.
Reduce and limit intake of caffeine, tobacco, and other stimulants to the earlier part of the day. Discontinue nicotine and caf-
feine at least 4 to 6 h before bedtime
Avoid alcohol as a sleeping aid
Regularize sleep-wake schedule, meal times, and exercise time
Exercise daily, but not closer than 3 h before bedtime
If racing thoughts predominate during bedtime, set aside 15- to 20-min “worry time” earlier during the day. Use this to think
about or list worries, problems, concerns, etc
Avoid work-related or strenuous activities close to bedtime
Engage in relaxing, pleasant activities 1 to 2 h before bedtime to “wind down” from the stresses of the day. Focus on positive
thoughts at bedtime
Minimize noise, light, and excessive temperature during sleep. If needed, use earplugs, eye shades, or an electric blanket/air
conditioner
Go to bed only when sleepy
If sleep restriction is chosen as a treatment option, determine average estimated sleep time. Restrict the time in bed to the
average estimated sleep time and continue with the weekly sleep diary. Using the sleep diary, determine the sleep efficiency
(total sleep time/time in bed x100%) each week. Increase time in bed by 15 to 20 min when sleep efficiency >90%. Decrease
time in bed by 15 to 20 min when sleep efficiency <80%. Maintain time in bed if sleep efficiency is 80% to 90%. Adjust the time
in bed each week until the ideal sleep duration is obtained. The minimum time in bed is 5 h per night
Use the bedroom only for sleep and sex. Do not read or watch TV in bed
Get out of bed and go into another room when unable to fall asleep or return to sleep within 15 to 20 min. When out of bed,
engage in relaxing and pleasant activities in a dimly lit room. Return to bed only when sleepy again. If still unable to sleep,
repeat the same instructions
Maintain a regular arising time in the morning regardless of how much or how little sleep you got during the prior nights.
Expose yourself to outdoor light for 30 min within 15 min of arising
Avoid daytime napping unless there are safety issues. If so, take a short early afternoon nap (less than 1 h)Circadian rhythm disorders
Delayed and advanced sleep phase disorders
Disorders of circadian sleep-wake rhythms can present
with complaints of chronic insomnia as well as excessive
daytime somnolence.
4,7,49-54 Delayed sleep phase syndrome
sufferers report inability to fall asleep until the early morn-
ing hours and difficulty arising until late morning or early
afternoon;sleep is normal after onset.PSG shows delayed
sleep latency if the sufferer sleeps at the desired bedtime
rather than the usual bedtime.In contrast,advanced sleep
phase syndrome sufferers complain of severe inability to
delay their bedtime (usually between 6 PM to 9 PM) and
subsequent awakening earlier than desired (often between
1 AM to 3 AM).
4,7,49,54 PSG performed at the person’s desired
bedtime reveals shortened sleep latency and early morn-
ing awakening.
Patients with delayed and advanced sleep phase insomnia
can be treated with proper timing of bright light and
behavioral changes.
4,7,49 The goal of light therapy is to
entrain the endogenous sleep-wake rhythm to coincide
with the patient’s social and occupational schedule.
Melatonin administration can be utilized to entrain free-
running circadian rhythms and may be helpful in blind
subjects.
51
For delayed sleep phase syndrome patients,Dahl utilizes
chronotherapy with cognitive behavioral therapy to
advance the sleep phase,employing successive 3-h delays
in bedtime for 6 days.
47To minimize school or work dis-
ruption,he prefers to start on a Thursday (Table III).
To phase delay the circadian clock for advanced sleep
phase syndrome patients,combine bright light exposure
(10 000 lux for 30-45 min) between 7 and 9 PM together
with a 15-min delay in bedtime every few days.
7 Once the
desired schedule is achieved for either phase delay or
phase advance,it is crucial to lock in the wake-up time to
maintain a stable sleep-wake rhythm.The benefit of light
therapy is dependent upon the magnitude of light inten-
sity and exposure time.Either natural outdoors light or
a light box (10 000 lux) or light visor (3000-5000 lux) can
be utilized,with minimum exposure of at least 30 min.
Shift work sleep disorder
Shift work sleep disorder sufferers complain of difficulty
initiating or maintaining sleep or poor quality sleep or
excessive sleepiness that is temporally related to a work
period that occurs during the habitual sleep phase.
4,7,55
These patients are chronically fatigued and have an
increased incidence of accidents at work.Shift workers
have a higher incidence of chronic depression,emotional
problems, family life dysfunction, excessive drug and
alcohol use,ulcers,and myocardial infarction compared
to the general population. Disturbances in circadian
rhythms with internal desynchrony secondary to work
shift time changes or sleep loss are postulated to cause
this disorder.PSG shows increased sleep latency,numer-
ous arousals during sleep,and early awakening,as well as
sleep efficiency below 85%.
4,7
A twofold approach to shift work problems involves
treatment directed individually toward the patient, in
addition to attempts to encourage the workplace
(through occupational medicine and workers compensa-
tion programs) to adapt to the worker’s needs and
reduce the overall incidence of shift work–related sleep
disorders.
55-60 Treatment recommendations include the
following:maintain a regular sleep and meal schedule;
take naps to limit sleep loss; and practice good sleep
hygiene.If sleep is necessary during daylight hours,opti-
mize sleep by darkening the room and screening for
noise and interruptions. Light environment is impor-
tant—exposure to bright light during the first portion of
the shift and protection from bright light after work (sun-
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Table III. Chronotherapy instructions to advance sleep phase.
47 
Patient takes responsibility for the success of the treatment and reorganizes habits and associations to improve sleep hygiene.
Cognitive behavioral therapy focuses on positive thoughts at bedtime
For adolescents, behavioral contract with parents/guardian specifies rewards and consequences
One-week induction phase. Stay up the whole night on Wednesday. Bedtime schedules are as follows: Thursday 6 AM to 3 AM,
Friday 9 AM to 5 AM, Saturday 12 noon to 8 AM, Sunday 3 AM to 12 midnight, Monday 6 AM to 2 AM, Tuesday and thereafter 9 AM to
6 AM. Stay in bed between 8.5 and 9 h
Maintenance phase. Adhere to the schedule rigidly for at least 1 month. After this, allow minor changes during the weekend
(wake-up time is still within 2 h of school or work time). Only permit one late night on the weekend, but impose strict wakeup
within 2 h of school or work time. No napping is allowedglasses) and before sleep may be beneficial.Short–half-
life hypnotics can be used by those who only occasion-
ally work shifts to help initiate sleep;chronic hypnotic
use by long-term shift workers is not encouraged.
7,55
Disorders of excessive somnolence
Sleep apnea,hypopnea,and upper airway resistance 
syndrome
Apnea is defined as cessation in airflow for longer than
10 s.Hypopnea refers to an abnormal respiratory event
lasting longer than 10 s associated with at least a 30%
reduction in thoracoabdominal movement or airflow
compared to baseline,associated with ≥4% oxygen desat-
uration.
61 Figure 1 demonstrates hypopneas seen during
PSG monitoring of a patient with sleep apnea.Apneas
and hypopneas are combined to form the AHI (ratio of
total apneas and hypopneas to the total sleep time in
hours), also known as respiratory disturbance index
(RDI).An AHI>5 in an adult is abnormal.Apneas and
hypopneas can result from upper airway obstruction
(obstructive),loss of ventilatory effort (central),or a mix-
ture of both (mixed).OSAS is characterized by repetitive
episodes of upper airway obstruction that occur during
sleep,usually associated with oxygen desaturation.
4The
clinical features of OSAS are listed in Table IV. Some
patients have increased upper airway resistance without
observed apneas or hypopneas and exhibit increased res-
piratory effort with Pes (esophageal pressure) crescendos
and Pes reversals.Guilleminault et al described the upper
airway resistance syndrome (UARS) in patients who had
Pes-documented increased respiratory effort associated
with increased arousals and daytime sleepiness.
62-64
Sleep-disordered breathing (OSAS and UARS) in chil-
dren peaks between ages 2 to 5 with a second peak in
Clinical research
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Figure 1. Hypopnea in a patient with obstructive sleep apnea syndrome. Note the low amplitude signals seen in the nasal cannula and airflow chan-
nels with increasing effort demonstrated on the chest and abdominal (Abd) channels. The Pes (esophageal pressure [PES]) channel shows
crescendo increases in esophageal pressure with reversal.
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middle to late adolescence.Continuous snoring,failure
to thrive,mouth breathing,enlarged tonsils and adenoids,
and predominance of hypopneas rather than apneas are
common features in childhood OSAS.
62,65-68 Children with
sleep-disordered breathing have a threefold increase in
behavioral and neurocognitive abnormalities.It has been
estimated that 5% to 39% of attention-deficit/hyperac-
tivity disorder (ADHD) could be attributed to sleep-dis-
ordered breathing.
65-69
In OSAS,the PSG demonstrates more than five obstruc-
tive apneas per hour of sleep and one or more of the fol-
lowing: frequent arousals associated with the apneas;
bradytachycardia; and arterial oxygen desaturation in
association with the apneas.Sleep architecture in OSAS
and UARS patients is abnormal with fragmented sleep
(mainly during non–rapid eye movement [NREM] stages
I and II) and frequent arousals and awakenings. The
amount of SWS (NREM stages III and IV) and REM
sleep is decreased.
4,7 MSLT performed the day after the
PSG may or may not demonstrate sleepiness (ie,mean
sleep latency <10 min).
Treatment for OSAS consists of nonsurgical as well as
surgical treatments.Nonsurgical treatment encompasses
general/behavioral measures,such as weight loss,body
position during sleep (avoid supine position), and
mechanical measures,which include continuous positive
airway pressure (CPAP) or bilevel positive airway pres-
sure (BIPAP) and oral appliances.
A consensus statement by Loube and colleagues recom-
mended CPAP treatment for all OSAS patients with
RDI≥30 regardless of symptoms and for patients with
RDI=5 or 30 events per hour if accompanied by symp-
toms of excessive daytime somnolence,impaired cogni-
tion,mood disorders,insomnia,or documented cardio-
vascular diseases (ischemic heart disease,hypertension),
or stroke.
70 Improvement or elimination of apneas
improves sleep architecture and reduces daytime sleepi-
ness.
71,72 Beneficial effects of CPAP or surgery reported
in patients with frequent sleep apneas (>20) and patients
with sleep-disordered breathing (RDI<20) without sub-
jective pathological sleepiness include improvement in
well-being,mood,functional status,breathing,oxygen sat-
uration,and cardiac rhythm.
71-76 CPAP has also been suc-
cessfully utilized to treat OSAS in infants and children
younger than 2 years of age.
77,78 However, compliance
with CPAP is problematic,with published rates ranging
from 65% to 95% when assessed subjectively.
79-87 Strollo
and colleagues have recommended management strate-
gies for common side effects of nasal CPAP.
80
Autotitrating continuous positive airway pressure
(APAP) can be used to treat many patients with OSAS
or to identify an effective optimal fixed level of CPAP for
treatment,but is not recommended for patients with con-
gestive heart failure,chronic obstructive pulmonary dis-
ease, daytime hypoxemia and respiratory failure from
any cause, or prominent nocturnal desaturation other
than from OSAS.
88,89 Indications for BIPAP include intol-
erance of CPAP,development of central apneas resulting
in sleep fragmentation,mask leaks at a high CPAP pres-
sure,and persistent alveolar hypoventilation.
80 Patients
with OSAS on CPAP or BIPAP should be reevaluated at
regular intervals to assess compliance,address problems,
and reinforce the importance of continued treatment.
Surgery is indicated for OSAS patients who have an
underlying specific surgically correctable abnormality
that is causing sleep apnea and may be indicated in
Cardinal symptoms Other symptoms Physical examination findings
- Excessive sleepiness or insomnia
- Frequent episodes of obstructed 
breathing during sleep
- Loud snoring
- Morning headaches
- Dryness of the mouth or sore throat on
awakening
- Nonrestorative sleep
- Gasping or choking at night
- Gastroesophageal reflux
- Sexual dysfunction with decreased
libido and impotence
- Cognitive deficits with memory and
intellectual impairment
- Decreased vigilance
- Mood changes with either depression 
or anxiety
- Increased body mass index (BMI)
- Nasal obstruction
- High-arched hard palate
- Low hanging soft palate
- Large or long uvula
- Crowded and small oropharynx with or
without enlarged tonsils and adenoids
- Malocclusion of the jaw with overjet
- Micrognathia, retrognathia, mandibular
hypoplasia
- Macroglossia, scalloping of the tongue
- Neck circumference >44 cm in men
- Brachycephalic head shape
Table IV. Clinical features of obstructive sleep apnea syndrome.patients who are not candidates for or have failed other
noninvasive treatments,desire surgery,and are medically
stable.
90 Identification of the site(s) of obstruction is nec-
essary in choosing the appropriate surgical intervention.
Methods of localizing the site of obstruction include
endoscopy, pressure catheters, fluoroscopy, computed
tomography (CT) scan, or magnetic resonance imaging
(MRI).
91 Surgical procedures can be divided into phase I
and phase II surgical procedures.
92-96 Phase I involves
palatal and lingual surgery: tonsillectomy, uvulo-
palatopharyngoplasty (UPPP),uvulopalatal flap (UPF),
modified UPPP, palatal advancement, genioglossus
advancement, hyoid suspension, laser midline glossec-
tomy, lingualoplasty, and radiofrequency of the soft
palate and tongue base. Phase II procedures either
advance the jaws (maxillomandibular osteotomy) or
widen the jaws using distraction procedures.
Central sleep apnea is characterized by either shallow or
absent breathing during sleep associated with one of the
following features:gasping,grunting,choking movements,
frequent body movement,and cyanosis.The PSG shows
central apneic pauses >10 s (20 s in infancy) in duration,
with one or more of the following:bradytachycardia;fre-
quent arousals from sleep;or oxygen desaturation asso-
ciated with apneas.
4 MSLT may or may not demonstrate a
mean sleep latency <10 min.Treatment of central sleep
apnea involves treatment of comorbid medical conditions
(congestive heart failure,nasal congestion,OSAS),con-
sideration of supplemental oxygen (1-2 L/min via nasal
cannula), or use of acetazolamide (125-250 mg, two to
three times per day).
7 Patients with central apneas before
and after an arousal, without evidence of desaturation,
may benefit from a trial of a hypnotic agent (zolpidem,
5-10 mg at night).
7
RLS and PLMD
RLS has a prevalence of 10% to 15% among patients
between the ages of 27 to 41 years.
97 It consists of
unpleasant creeping or crawling sensations inside the
calves and generalized aches and pains in the legs asso-
ciated with a desire to move the extremities,motor rest-
lessness,worsening of symptoms at rest with at least tem-
porary relief by activity, nocturnal worsening of
symptoms (circadian pattern), and difficulty initiating
sleep in the absence of any medical, mental, or other
sleep disorder that would account for the symptoms.
97-99
RLS can be idiopathic or secondary to iron deficiency,
peripheral neuropathies,or uremia.There are two rec-
ognized phenotypes in the idiopathic category: early-
onset RLS starts before age 45 and progresses slowly,
demonstrating autosomal dominant inheritance, while
late-onset RLS starts after age 45 and progresses rapidly,
with limited familial aggregation.
101 Increased cere-
brospinal fluid (CSF) hypocretin-1 levels are present in
early-onset RLS patients, whereas levels in late-onset
RLS patients are normal. Allen et al postulate that
increased hypocretin levels may modulate or promote
insomnia and increase motor activity.
101
RLS involves various areas in the nervous system from the
spinal cord up to the basal ganglia.
98,101,102 Using single
photo emission computed tomography (SPECT) and
positron emission tomography (PET),various researchers
have demonstrated a decrease in dopamine D2 receptor
binding in the striatum of RLS patients,suggesting that
RLS is related to a deficiency of dopaminergic func-
tion.
97,100,102-104 Iron deficiency accompanying RLS may be
associated with hypofunction of the D2 receptor.
97,100
More than 80% of RLS patients manifest periodic limb
movements (PLMs) during sleep.
100 PLMs consist of four
or more repetitive episodes of muscle contraction (0.5-
5 s in duration) separated by an interval (≥5 s but <90 s),
which may be associated with an arousal.A PLM index
(events/hour) >5 is abnormal.Tricyclic antidepressants,
lithium, and selective serotonin reuptake inhibitors
(SSRIs) can increase PLMs.
Saletu and colleagues performed EEG mapping in RLS
patients and demonstrated an increase in both absolute
δ and absolute and relative α2 power, a decrease in
absolute and relative α1 power, an acceleration of the
dominant frequency and the α centroid,and a slowing of
the δ/θ centroid,as well as a nonsignificant attenuation
in total power.
105These findings are characteristic of dis-
sociated vigilance changes described in depression and
correlated with higher depression and anxiety scores,
lower quality of life, and deteriorated sleep quality
despite normal Epworth Sleepiness scale scores.
Treatment options for RLS include dopaminergic agents
(pramipexole,ropinirole,pergolide,levodopa/carbidopa),
opioids (oxycodone, propoxyphene), benzodiazepines
(clonazepam), anticonvulsants (gabapentin, carba-
mazepine),and clonidine.
97,102,106-117 Patients with low serum
ferritin levels may benefit from iron therapy.
Treatment with dopaminergic agents is complicated by
rebound (worsening of symptoms at the end of the dos-
ing period with late night or morning recurrence of
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symptoms seen with long-term use, particularly with
higher doses,presenting with earlier time-of-day onset of
symptoms and expansion of symptoms beyond the legs).
With levodopa,rebound occurs in 20% of RLS patients,
while augmentation affects 82% of patients;augmenta-
tion is increased in patients with more severe RLS and in
those receiving higher doses.
7,106,117 Dopamine agonists are
useful in treating patients with RLS.
108 Pergolide therapy
reduced PLMs and increased total sleep time in 83% of
RLS patients, but mild augmentation also occurred.
Augmentation may be managed through a combination
of behavioral strategies (walking and other physical
activities) and medication-timing strategies.
7,102
Narcolepsy
Westphal described the first unequivocal case of nar-
colepsy in 1877,and Gelineau coined the term narcolepsy
in 1880.The prevalence of narcolepsy in the United States
is 1/2000.
3,118 Narcolepsy is a neurological disorder that
affects men and women equally,with usual age of onset
between 15 and 30 years.It is characterized by the follow-
ing tetrad of symptoms: excessive daytime somnolence
(EDS),which can be a continuous feeling of sleepiness or
“sleep attacks,” cataplexy, hypnagogic or hypnapompic
hallucinations,and sleep paralysis.
4,118-125 Guilleminault et al
reported that EDS alone or in combination with sleep
paralysis or hypnagogic hallucinations is the initial symp-
tom in 90% of patients and that 5% to 8% of patients pre-
sent with cataplexy.
126,127 Only 10% of patients experience
the full tetrad.
119
After onset,EDS persists daily,although it can fluctuate
during the day in a stereotyped individual pattern.
Attention fluctuates modulated by situational circum-
stances.The attack usually starts with drowsiness asso-
ciated with blurry or double vision and usually lasts for
less than 20 min.Sleepiness is often relieved by a sleep
attack,but the relief lasts for only several hours.
Cataplexy involves sudden bilateral atonia of striated
muscles with partial or complete weakness that is
brought on by emotion or excitement. Laughter is the
most typical trigger and,less frequently,anger or surprise.
Other triggers include anticipation of something special
or hilarious, attempts at bantering, feeling amused, or
immobility in response to a call for immediate action.The
patient’s “state” and circumstances also influence
whether an attack occurs: sleep deprivation or strong
feeling of sleepiness can lower the attack threshold.The
attacks start abruptly,but take several seconds to reach
their maximum, with most attacks lasting less than a
minute.During partial attacks,the knees may give way
and there may be sagging of the jaw, inclination of the
head,and weakness of the muscles responsible for speech
so that the patient is either unable to speak or has slurred
speech. Even with severe attacks, eye movements and
respiration are spared.Neurological examination during
the attack shows atonia, loss of tendon reflexes, and
extensor plantar responses.Prolonged episodes may be
associated with hallucinations and rarely,“status cata-
plexicus.” Video-polygraphic analysis of cataplectic
attacks demonstrate three phases:(i) initial phase,con-
sisting of arrest of eye movements and phasic,massive,
inhibitory muscular events;(ii) falling phase,character-
ized by a rhythmic pattern of suppressions and enhance-
ments of muscular activity leading to the fall; and (iii)
atonic phase,associated with complete muscle atonia.
128
Injury is uncommon because most people are able to find
support or sit down at the onset of the attack.A consis-
tent individual pattern is seen.Attacks vary in frequency
from more than 10 per day to less than 1 per month.
Hypnagogic hallucinations (at sleep onset) or hypnapom-
pic hallucinations (on waking) represent vivid dreamlike
experiences of visual imagery (constant or changing col-
ored forms),auditory hallucinations,or tactile sensations.
Smell and taste are rarely affected.Some patients describe
out-of-body experiences at sleep onset.Attacks usually last
less than 10 min,and the frequency varies from less than
once a month to more than once a day.
Sleep paralysis represents inability to move either at
sleep onset or upon awakening;the episode can last up
to 10 min. Patients can be frightened because they are
unable to open their eyes or move their fingers and feel
they have to struggle to move.
Disturbed nocturnal sleep is the fifth component of the
“tetrad” and is due to frequent awakenings.Although
patients typically have short SOL,they may have trouble
returning to sleep once awakened.Other reported symp-
toms include automatic behavior (episodes of amnesia
associated with semipurposeful activity),subjective mem-
ory impairment that is not validated during standard
memory testing, tiredness or fatigue, blurry or double
vision,and sexual dysfunction (which may be related to
drug therapy).
124
The PSG demonstrates SOL less than 10 min and REM
sleep latency less than 20 min.
4An MSLT demonstrates
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sleep-onset REM (SOREM) episodes.
4 Figure 2 depicts
SOREM during an MSLT nap.
HLA typing demonstrates an increased frequency of
DQB1*0602 or DR2 in patients with narcolepsy,especially
with cataplexy.Low CSF levels of hypocretin-1 are highly
associated with narcolepsy with cataplexy (89.5%),par-
ticularly in patients with cataplexy who are HLA
DQB1*0602–positive (95.7%).
129-132
Stimulant medications are the mainstay of treatment of
EDS,with the objective of allowing the fullest possible
return of normal function for patients at work,home,and
school.
118,122,123,125,133-135The most common stimulants used,
listed in incrementing order of relative efficacy are:
pemoline,modafinil,dextroamphetamine,methamphet-
amine,and methylphenidate.
133,135The maximum recom-
mended daily dosages of stimulants in adults are: dex-
troamphetamine sulfate, 100 mg; methamphetamine
hydrochloride, 80 mg; and methylphenidate, 100 mg.
133
Pemoline was utilized in the past,but is not currently rec-
ommended due to concerns about the risk of acute
hepatic failure.
7Apart from modafinil,all stimulants are
centrally acting sympathomimetic agents that enhance
the release of monoamines in the synaptic cleft and block
their reuptake.
133,134 Modafinil is a novel stimulant with an
uncertain mechanism of action that may increase
dopamine signaling.
136 For newly diagnosed narcoleptics,
modafinil may represent a reasonable initial choice
because of its long duration of action,low frequency and
severity of side effects,and low potential for dependence
or tolerance. However, patients should be cautioned
about drug interference with other medications,such as
oral contraceptives.There are no well-controlled studies
of pregnant women using stimulants.The benefits for the
patient have to be weighed against the potential risks for
the fetus.Mitler and colleagues recommend dosage reduc-
tion or discontinuation of stimulants during attempts at
conception and during pregnancy.
133
REM-suppressant drugs are utilized in the treatment of
cataplexy,hypnagogic hallucinations,and sleep paralysis.
Drugs that block norepinephrine reuptake,such as the
tricyclic antidepressants,protriptyline,clomipramine,and
imipramine,have been effective,but are frequently asso-
ciated with tolerance and anticholinergic side effects.
Tricyclics should not be discontinued abruptly because of
the risk of severe aggravation of cataplexy,including sta-
tus cataplecticus.
136 SSRIs such as fluoxetine,paroxetine,
and citalopram are also effective.Venlafaxine,a norepi-
nephrine/serotonin reuptake inhibitor,is highly effective
and well tolerated.
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Figure 2. Sleep-onset rapid eye movement (REM) during an mean sleep latency test (MSLT) nap in a patient with narcolepsy. Electroencephalogram
(EEG) leads (C3-A2 and O2-A1) demonstrate low voltage mixed frequency theta activity. EMG-Chin shows atonia with phasic events. Electro-
oculography (EOG) demonstrates REM.
C3-A2
O2-A1
REM
EKG
EMG-Chin
LOC-A2
ROC-A1γ-Hydroxybutyrate (GHB),a short-acting putative neuro-
transmitter that acts as a hypnotic, reduces cataplexy,
hypnagogic hallucinations, and subjective sleepiness.
Three to nine grams of GHB is administered in bed with
half of the dose at bedtime and the remainder 2.5 to 3 h
later. Nausea, dizziness, and incontinence have been
reported with high doses.Due to the risk of precipitating
confusional arousals and even coma,doses >9 g should
never be prescribed.Triazolam may be useful in treating
insomnia in narcoleptics by increasing total sleep time
and sleep efficiency without affecting alertness the fol-
lowing day.
137
Nonpharmacological therapy includes regular sleep and
wake times, short scheduled naps, prevention of sleep
deprivation, avoidance of shift work, and working in a
stimulating environment.Narcoleptic patients need to be
cautioned about driving risks when undertreated.
Idiopathic hypersomnia
Idiopathic hypersomnia is a clinically heterogeneous dis-
order of chronic sleepiness without cataplexy that has a
prevalence of 2 to 5/100 000.
138,139 Symptoms present
between ages 15 to 30 years and include variable daytime
drowsiness (nonimperative versus irresistible),naps that
range from short and refreshing to long and unrefresh-
ing, prolonged nighttime sleep >12 h or restless sleep
with frequent arousals,sleep “drunkenness,”and auto-
matic behavior associated with blank stares and
microsleep episodes.
4,138,139
Three subgroups of patients are recognized.Subgroup 1
consists of patients with HLA Cw2 antigen and a posi-
tive family history of EDS associated with autonomic
dysfunction (syncope,orthostatic hypotension,Raynaud-
type phenomena).Subgroup 2 consists of individuals who
had a viral illness (Guillain-Barre,mononucleosis,hepati-
tis,atypical viral pneumonia) followed by persistent EDS.
Subgroup 3 includes patients with no family history or
viral infection prior to onset of EDS.The PSG demon-
strates a combination of normal or long nocturnal sleep,
and the MSLT performed the day after the PSG shows
short SOL without sleep-onset REM periods.
139 Pharma-
cological treatment involves use of stimulants,starting
with either modafinil or methylphenidate and switching
to dexedrine spansules if initial treatment is ineffective.
Nonpharmacological treatment includes one scheduled
daily nap (noon or late afternoon) no longer than 45 min;
avoidance of alcohol,sleep deprivation,heavy meals and
shift work; and observance of regular sleep (at least 
8.5 h per night) and wake schedules.
Parasomnias
Parasomnias are characterized by undesirable physical
phenomena or behaviors that occur predominantly dur-
ing sleep.Skeletal muscle activity and autonomic nervous
system changes are prominent. Parasomnias are com-
posed of disorders of arousal,partial arousal,and sleep-
stage transition (Table I).
Disorders of arousal are the most common form of para-
somnia.They usually occur during SWS (NREM stages
III and IV),and symptoms typically present in the first
third of the night. Studies of twin cohorts and families
with sleep terror and sleepwalking suggest that genetic
factors may be involved,and there may be a family history
of the same or other NREM arousal parasomnia.
140-142
Factors that increase SWS, such as young age, natural
deep sleeper, recovery from sleep deprivation, central
nervous system (CNS) depressant medications (seda-
tives, hypnotics, alcohol), fever, and the hypersomniac
period in Kleine-Levin syndrome, may aggravate the
arousal disorder.Factors that lead to sleep fragmentation,
including stress,environmental stimuli,endogenous stim-
uli, pain, pregnancy, stimulants, thyroxine taken in the
evening, migraine headaches, or Tourette’s syndrome,
may trigger the parasomnia.
Confusional arousals (nocturnal sleep drunkenness)
This disorder is more common in children younger than
5 years of age,becomes less frequent during adolescence,
and is rare in adulthood.The patient partially awakens
from a deep sleep during the first third of the night, is
confused and slow in mentation,disoriented to time and
space, poorly/partially responsive to external stimuli,
manifests automatic behavior (picking at bedclothes),
and moans and mumbles incomprehensibly.Attacks last
from 30 s to 10 min, and the patient is amnesic for the
behavior and for any dream-like or thought-like menta-
tion.PSG shows movement arousal in SWS followed by
decreased amplitude of the EEG and the appearance
during the period of mental confusion of either NREM
stage I or a diffuse α that is slower by 1 to 2 Hz compared
to that of wakefulness.Confusional arousals in children
do not necessarily warrant treatment. In adults who
exhibit aggression towards others or self-injury, room
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safety precautions need to be implemented and condi-
tions facilitating or triggering attacks need to be avoided.
The attacks should be allowed to terminate sponta-
neously.Benzodiazepines or tricyclic medications may be
useful as short-term therapy for a few days or weeks dur-
ing periods when attacks are more common.
Sleep terrors
The peak prevalence of sleep terrors is between 5 and 7
years of age.By age 8,half of the children are attack-free,
while 36% continue to have attacks until adolescence.
Episodes of sleep terror occur during the first third of the
night and also during daytime naps.The child sits up,emits
a piercing scream,and appears frightened,with increased
pulse and respiratory rates and profuse sweating. The
episodes last from 30 s to 5 min,and the child is amnesic
for the events during the episode.PSG shows explosive
arousal with marked increases in muscle tone,heart rate,
and respiratory rate, and a rapid decrease in skin resis-
tance. Facilitating and precipitating factors need to be
avoided.Treatment may include either a short-acting ben-
zodiazepine,such as midazolam (10-20 mg),oxazepam (10-
20 mg),or clonazepam (0.5-2 mg).Patients unresponsive
to benzodiazepines may benefit from tricyclic antidepres-
sants such as clomipramine,desipramine,or imipramine
(10-50 mg at hour of sleep).If total control of the episodes
occurs and is sustained over several months,a slow and
progressive withdrawal of medication may be performed.
Sleepwalking (somnambulism)
The patient ambulates during sleep,is difficult to arouse
during an episode,and is usually amnesic following the
episode.Guilleminault et al indicated that children over
the age of 4 reported vague memories of having to act,
run away,escape or defend themselves against monsters,
animals,snakes,spiders,ants,intruders,or other threats,
and that they felt completely isolated and fearful.
143,144
Episodes usually occur in the first third of the night dur-
ing SWS.
4,143,144 This disorder has a peak age of onset at 
5 years of age and peak prevalence at about 12 years.
Most children outgrow the episodes by age 15. PSG
recordings demonstrate 2 abnormalities during the first
sleep cycle:frequent,brief,nonbehavioral EEG-defined
arousals prior to the somnambulistic episode and abnor-
mally low δ (0.75-2.0 Hz) EEG power on spectral analy-
sis, correlating with high-voltage “hypersynchronic δ”
waves lasting 10 to 15 s occurring just prior to the move-
ment.
140,142-145This is followed by stage I NREM sleep,and
there is no evidence of complete awakening.
REM behavior sleep disorder
In REM behavior sleep disorder (RBD),the patient com-
plains of violent or injurious behavior during sleep with
disruption of sleep continuity and excessive motor activ-
ity during dreaming,accompanied by loss of REM sleep
EMG atonia.
4,145-151 The frequency of nocturnal events
varies from several times a night to once every 3 months.
The most common behaviors consist of arm flailing and
punching,kicking,and vocalizations;these behaviors occur
in bed or result in falling out of bed. About 32% of
patients report self-injury ranging from falling out of bed
to striking or bumping into the furniture or walls.Olson
reported one patient attempted to fire an unloaded gun,
while another attempted to set fire to his bed.
147 Sixty-four
percent of spouses report being assaulted during sleep.
147
Dream content in RBD has aggressive themes in about
89% of patients,with the most common one being defense
of the sleeper against attack.Although RBD is usually
idiopathic, it can occur secondarily on a transient or
chronic basis.Acute RBD can result from drug withdrawal
(meprobamate,pentazocine,nitrazepam,and butalbital)
152
or intoxication (biperiden,tricyclic antidepressants,mono-
amine oxidase [MAO] inhibitors,or caffeine).
149,153 Chronic
RBD can be produced by drugs (tricyclic antidepressants,
fluoxetine,venlafaxine,mirtazapine,selegeline,and anti-
cholinergic medications),vascular problems (subarachnoid
hemorrhage, vasculitis), tumors (pontine neoplasms,
acoustic tumors), infectious/postinfectious diseases
(Guillain-Barre),degenerative or demyelinating condi-
tions (amyotrophic lateral sclerosis,fatal familial insom-
nia,dementia,Parkinson’s disease,multiple sclerosis,olivo-
pontocerebellar degeneration, Shy-Drager syndrome,
multiple system atrophy),and developmental,congenital,
or familial diseases (narcolepsy, Tourette’s syndrome,
Group A xeroderma pigmentosum, mitochondrial
encephalomyopathy).
147,149,153-155 Because of the overwhelm-
ing male preponderance (90%),questions of relationships
between sexual hormones,aggression,and violence have
been raised.
148,149 Diffuse lesions of the hemispheres,bilat-
eral thalamic abnormalities,or primary brain stem lesions
may result in RBD.
150
The PSG shows at least one of the following:excessive
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phasic EMG twitching associated with one or more of
the following:excessive limb or body jerking,complex
vigorous/violent behaviors,and absence of epileptic activ-
ity in association with the disorder.Shirakawa and col-
leagues performed MRI and SPECT imaging on 20
patients with RBD and reported decreased blood flow in
the upper portions of the frontal lobe and pons.
156Albin
and colleagues found decreased striatal dopaminergic
innervation in RBD patients.
157
Treatment of RBD has been effective in 90% of patients
using clonazepam starting at 0.5 mg at bedtime and grad-
ually incrementing the dose until control is effected.
Other drugs, such as gabapentin, clonidine, carba-
mazepine,donezepil,levodopa,and melatonin have been
anecdotally reported to be useful.
149,158-162
Environmental safety measures are very important.
Potentially dangerous objects should be removed from
the bedroom, weapons (if any) should be stored and
locked away safely outside the bedroom with the key
entrusted to another person,the corners around the bed
should be padded or cushioned, the mattress may be
placed on the floor, and window protection should be
considered.
Conclusions
Sleep disorders constitute a ubiquitous group of diseases
that have important consequences for individual health
as well as economic costs to society. The diagnosis of
sleep disorders requires careful history taking,examina-
tion,and laboratory testing.Although general guidelines
in management for the more common and important
sleep disorders have been discussed,treatment needs to
be tailored to the individual patient. ❏
Diagnóstico y tratamiento de los trastornos
del sueño: una breve revisión para los clínicos
Los trastornos del sueño incluyen un amplio espec-
tro de enfermedades con consecuencias significati-
vas para la salud individual y altos costos económi-
cos para la sociedad. Para facilitar el diagnóstico y
tratamiento de los trastornos del sueño esta revi-
sión se estructuró utilizando la Clasificación
Internacional de Trastornos del Sueño. Se diferen-
cia el insomnio primario y secundario, y se discuten
los tratamientos farmacológicos y no farmacológi-
cos. Se describen los trastornos comunes del ritmo
circadiano en conjunto con intervenciones que
incluyen la cronoterapia y la fototerapia. También
se revisa el diagnóstico y tratamiento del síndrome
de las piernas inquietas o trastorno del movimiento
periódico de las piernas. Además se centra la aten-
ción en la apnea obstructiva del sueño y el sín-
drome de resistencia de la vía aérea superior y su
tratamiento. Se revisa la constelación de síntomas
y hallazgos de la narcolepsia, junto con las pruebas
diagnósticas y la terapia. Se describen las parasom-
nias, incluyendo los terrores nocturnos, el sonam-
bulismo y los trastornos de conducta asociados al
sueño REM (movimiento rápido de ojos) junto con
los resultados de las pruebas de laboratorio y el tra-
tamiento.
Diagnostic et traitement des troubles du
sommeil : brève revue pour les cliniciens
Les troubles du sommeil comprennent un large
spectre de maladies avec des conséquences signifi-
catives individuelles en termes de santé et un coût
économique élevé pour la société. Pour faciliter le
diagnostic et le traitement des troubles du sommeil,
cette revue fournit un cadre utilisant la classification
internationale des troubles du sommeil. Les insom-
nies primaires et secondaires sont différenciées et les
traitements pharmacologiques et non pharmacolo-
giques sont discutés. Les troubles courants du rythme
circadien sont décrits conjointement avec les inter-
ventions dont la chronothérapie et la luxthérapie. Le
diagnostic et le traitement du syndrome des jambes
sans repos/mouvements périodiques des membres
sont abordés. Les apnées obstructives du sommeil et
le syndrome de résistance des voies aériennes supé-
rieures et leur traitement reçoivent une attention
particulière. La constellation de symptômes et les
acquisitions sur la narcolepsie sont passées en revue
ainsi que les épreuves diagnostiques et le traitement.
Les parasomnies dont les terreurs nocturnes, le som-
nambulisme et les perturbations des mouvements
oculaires rapides (REM, rapid eye movement) sont
décrits conjointement avec les résultats des tests de
laboratoire et le traitement.Clinical research
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